Neoplasms

All Conditions

Wounds and Injuries

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Digestive System Diseases

Rare Diseases

Carcinoma

Fractures, Bone

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Colonic Neoplasms

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Ovarian Cancer

Ovarian Epithelial Cancer

Central Nervous System Depressants

All Drugs and Chemicals

Anesthetics

patients treated by conventional haemodynamic care intraoperatively

patients treated within a goal-directed haemodynamic algorithm intraoperatively

Claudia Spies, MD Prof.

A systematic literature search a goal-directed haemodynamic algorithm was created. The hypothesis of this study was that the goal-directed haemodynamic algorithm is feasible and can improve clinical outcome.

After a systematic literature search a goal-directed haemodynamic algorithm was created. The algorithm was adapted to international standards and consensus was reached through a modified Delphi method at international meetings. The feasibility of using the algorithm for intraoperative haemodynamic management was tested and the resultant clinical data analyzed retrospectively for several types of surgery with the hypothesis that the goal-directed haemodynamic algorithm is feasible in the clinical setting and can improve clinical outcome.

An Algorithm for Intra-operative Goal-directed Haemodynamic Management in Non-cardiac Surgery

An Algorithm for Intra-operative Goal-directed Haemodynamic Management in Non-cardiac Surgery - a Feasibility Study

The perioperative hospital length of stay is assessed.

The perioperative need for ventilator therapy is assessed.

The monetary reimbursement for prolonged hospital stay is assessed to evaluate the impact on financial consequences.

Charite University, Berlin, Germany

Department of Anesthesiology and Intensive Care Medicine CVK/CCM, Charite University, Berlin

Skin and Connective Tissue Diseases

Breast Neoplasms

Analgesics

Dexmedetomidine

Hypnotics and Sedatives

Analgesics, Non-Narcotic

Adrenergic Agents

Adrenergic alpha-Agonists

Adrenergic Agonists

Neurotransmitter Agents

Patients were assigned to receive 0.9% saline intranasally 45 min before surgery using a computer-generated random number table.

Patients were assigned to receive 1µg.kg-1dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.

Patients were assigned to receive 1.5µg.kg-1 dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.

Patients were assigned to receive 2µg.kg-1 dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.

0.9% saline intranasally 45 min before surgery using a computer-generated random number table.

0.9% saline

dexmedetomidine 1µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.

dexmedetomidine 1µg.kg-1

Dexmedetomidine 1.5µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.

dexmedetomidine 1.5µg.kg-1

dexmedetomidine 2µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.

Dexmedetomidine 2µg.kg-1

This trial is going to evaluate the safety and effectiveness of intranasal DEX(dexmedetomidine) in breast lumpectomy under local anaesthesia,and to investigate the optimal dose of intranasal DEX in breast lumpectomy.

Breast lumpectomy associated with a high level of anxiety, fear and pain requires fast and effective anaesthesia techniques. Presently, this procedure is usually performed under general or local anaesthesia. General anaesthesia provides an effective sedation; however, for minor procedures, general anaesthesia is resource-intensive and postoperative complications, such as nausea, vomiting or extended time to ambulation, are more likely. Local anaesthesia alone may be uncomfortable or uncooperative for patients. Therefore, an efficient drug regimen is required that reduces analgesic consumption, minimises opioid-related side effects and shortens post-anaesthesia care unit (PACU) stay following surgery.

Dexmedetomidine (DEX) is a highly selective α2 adrenoreceptor agonist that provides sedation without respiratory depression. Its sedative, anxiolytic, analgesic and haemodynamic effects have made it a useful adjunct to anaesthesia and sedation. DEX may provide a conscious sedation under monitored anaesthesia care (MAC) that is a logical middle ground between general anaesthesia and local anaesthesia. Intranasal DEX was recently shown to provide satisfactory anaesthesia and premedication sedation in healthy volunteers and paediatric patients. The intranasal route is not only effective, but also well-tolerated and convenient This trial is going to evaluate the safety and effectiveness of intranasal DEX(dexmedetomidine) in breast lumpectomy under local anaesthesia, and to investigate the optimal dose of intranasal DEX in breast lumpectomy.

Efficacy and Optimal Dose Selection of Intranasal Dexmedetomidine During Breast Lumpectomy Under Local Anaesthesia

Tianjin Medical University Cancer Institute and Hospital

Anti-Arrhythmia Agents

Channel Blockers

Lidocaine

Analgesics, Opioid

CA (Conventional Anaesthesia) control group:

Anne-Claire COYNE, PhD

Mary SAAD, MD

Jane Muret, MD

jane Muret, MD

Migena DEMIRI, MD

This study will compare morphine consumption during the first 48 hours postoperatively between the OFA group and the CA control group.

Patient eligible for free flap reconstruction surgery of the breastunder general anaesthesia.

Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study.

Investigators will share de-identified data sets with interested researchers, educators or clinicians. Materials generated under the project will be disseminated in accordance with Institut Curie policies.

Institut Curie

Symptoms and General Pathology

Nervous System Diseases

Pain, Postoperative

Pain

Breast Diseases

Skin Diseases

Postoperative Complications

Neurologic Manifestations

Ropivacaine

Nalbuphine

For patients in PECS group (PG), after induction of general anesthesia, the nerve block will be performed using the ultrasound-guided technique described by Blanco and colleagues. Block will be performed with a 22-gauge 100 mm needle (Stimuplex, B. Braun Medical Inc., Pennsylvania, USA) using Mindray M7 imaging system (Diagnostic Instruments Inc., China) with a high-frequency (6-13 MHz) linear array transducer.20 mL of ropivacaine 0.25% in 5-mL increments will be injected, aspirating gently between injections. The needle will be withdrawn to place the tip in the fascial plane between the pectoralis major and pectoralis minor muscles and ropivacaine 0.25%, 10 ml in 5 ml increments will be injected. Injectate spread between the muscles will be visualized. For patients in control group, no nerve block will be performed and only intravenous nalbuphine will be given.

For patients in control group, after induction of general anesthesia, no nerve block will be performed and only intravenous nalbuphine will be given.

PECS nerve block will be performed using the ultrasound-guided technique described by Blanco and colleagues. Block will be performed with a 22-gauge 100 mm needle (Stimuplex, B. Braun Medical Inc., Pennsylvania, USA) using Mindray M7 imaging system (Diagnostic Instruments Inc., China) with a high-frequency (6-13 MHz) linear array transducer.20 mL of ropivacaine 0.25% in 5-mL increments will be injected, aspirating gently between injections. The needle will be withdrawn to place the tip in the fascial plane between the pectoralis major and pectoralis minor muscles and ropivacaine 0.25%, 10 ml in 5 ml increments will be injected. Injectate spread between the muscles will be visualized. For patients in control group, no nerve block will be performed and only intravenous nalbuphine will be given.

PECS Block

No nerve block will be performed and only intravenous nalbuphine will be given.

Control Group

Faisal Shamim, FCPS

Malika H. Dhanani, FCPS

Dr. Faisal Shamim, FCPS Anesthesiology

Breast cancer is the most common and leading cause of cancer deaths among females worldwide. Patients undergoing modified radical mastectomy (MRM) are associated with moderate to severe acute postoperative pain and shoulder mobility restriction.

This study aims to determine the effectiveness of ultrasound-guided PECS block for reducing opioid consumption, providing adequate postoperative pain management and improving patient satisfaction following breast cancer surgery.

The traditional pain management for patients undergoing MRM has relied heavily on opioids but a number of multimodal pain control strategies also exist including combining opioids with NSAIDs, cyclooxygenase-2 inhibitors, acetaminophen and regional blocks. Recently, literature underlines the importance of performing regional anaesthetic and analgesic techniques for postoperative analgesia following breast surgery. PECS (Pectoral nerve block) block provides analgesia for breast surgeries with few adverse effects.

OBJECTIVES To evaluate the effect of ultrasound guided pectoral block in reducing intraoperative and postoperative opioid consumption following modified radical mastectomy.

The secondary objective is to determine patient satisfaction levels associated with adequate pain control.

HYPOTHESIS Pectoral nerve blocks provides superior analgesia with less opioid consumption and improves patient satisfaction in postoperative period compared to conventional pain management for modified radical mastectomy patients

Effectiveness of Ultrasound Guided PECS Block on Opioid Consumption and Patient Satisfaction Through Adequate Pain Control Following Breast Cancer Surgery.

Effectiveness of Ultrasound Guided PECS Block on Opioid Consumption and Patient Satisfaction Through Adequate Pain Control Following Breast Cancer Surgery. A Prospective Randomized Controlled Trial

Patient satisfaction with post-operative analgesia will be noted via satisfaction scoring i.e.:

1. = Not Satisfied
2. = Good or satisfied
3. = Excellent or very satisfied

Numeric rating scale for pain assessment: Patient will be asked to rate their intensity of pain on numeric scale from 0 (no pain) to 10 (worst possible pain).

Aga Khan University

Associate Professor Anaesthesiology

Critical Illness

Disease Attributes

Control - Standard Perioperative Pathway, clinician decides post-operative care environment (usual care)

Intervention - Perioperative care pathway guided by CPX Results i.e.anaerobic threshold \& ventilatory equivalents

* AT \> 11ml/min/kg no myocardial ischaemia or Ve/VO2 \<35 - Level 1 Ward Care
* AT \> 11ml/min/kg with myocardial ischaemia or Ve/VO2 \>35 - Level 2/3 (ITU) Critical Care Unit
* AT \<11mls/min/kg - Level 2/3 Critical Care Unit
* AT \<8mls/min/kg - Level 2/3 Critical Care Unit/ consider cancellation or alternative procedure

Perioperative care pathway guided by CPX results

Michael PW Grocott

Paula Meale

Michael Mythen

Ayo Oshowo

Mervyn Singer

Geoff Bellingan

Kay Mitchell

Hasan Muktar

Alistair Windsor

Jim Down

Martin B Kuper

Denny ZH Levett

Phil Hennis, PhD

Alasdair O'Doherty, MSc

Alec Engledow

Aundrea Mulreany

Carolyn Dr Way

Karen Linford

Clare Bolger

Paul Nichols

Kim Golder

John S Knight

Michael Celinski

Grace Adesina

The investigators would like to evaluate the use of cardiopulmonary exercise tests (CPX) in guiding the care pathway of patients undergoing colorectal operations. In the intervention group care will be guided by CPX results and in the control group care will be guided by the doctors assessment. The investigators would like to assess the impact of this on patient outcome, patient satisfaction and resource usage.

Each year 20000 UK patients die within 30 days of surgery. It seems that in the UK a patient's chances of becoming seriously unwell or dying following surgery is higher than in comparable countries. Fewer beds in the UK are given over to Intensive Care than in these other countries. Closer attention to the care given after operations, which can be achieved on intensive care units (ICU), almost certainly reduces the chances of serious illness following major surgery. An increase in the number of intensive care unit beds in the UK is extremely unlikely. Better use of the available intensive care beds could be achieved by allocating them where they are believed to improve outcome (following surgery) and by allocating them to patients most likely to benefit.

Tests used to assess risk of surgery to patients are largely ineffective. Cardiopulmonary exercise tests (CPX) seem to be effective at identifying patients at risk of death or serious illness post surgery. This information has been used in studies to select patients for ICU beds and reduce deaths. The studies so far have limitations in their design and scope which means we can't be certain this approach works in the UK.

We suggest a study to answer this question more conclusively and more specifically in UK patients. We will randomly divide patients between two groups. In the 1st group choice of postoperative care environment is based on best current practice and in the other group we will make these decisions (critical care or ward) based on the results of the CPX.

We hope that the benefits will include less patients becoming seriously ill or dying and shorter stays in hospital after surgery following major operations. We also hope the information will help patients understand the risks of their operation better and therefore make better informed decisions. This may also reduce the overall cost of surgery for hospitals.

Cardiopulmonary Exercise Testing and Preoperative Risk Stratification

A Randomised Controlled Trial of the Utility of Cardiopulmonary Exercise (CPX) Testing for Preoperative Risk Stratification to Guide Perioperative Care and Thereby Reduce Postoperative Morbidity

University Hospital Southampton NHS Foundation Trust

University College London Hospitals

Professor

Carcinoma, Hepatocellular

Neoplastic Cells, Circulating

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Neoplasm Metastasis

Neoplastic Processes

Platelet Aggregation Inhibitors

Other Dietary Supplements

Rocuronium

Propofol

Sevoflurane

Atracurium

Remifentanil

Benzocaine

Anesthetics, Intravenous

Anesthetics, General

Anesthetics, Inhalation

Tannic Acid

Patients in SEVO group will be anaesthetized by inhalational anaesthesia using sevoflurane.

The patients in TIVA group will be anaesthetized using total intravenous propofol.

Monitoring and other anaesthetic procedures including the management of hypertension and hypotension will be the same as SEVO group. Induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Sevoflurane will not be used, and oxygen and air would be given to provide a FiO2 of 30-50%.

Target controlled infusion (TCI) with a modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia and titrated to effect. The usual effect site concentration is 1.5-3 mcg.ml-1 and BIS monitoring will also be used to produce a value of between 40-60. As with patients in the SEVO group, remifentanil will be infused at a rate of between 0.1-0.3 mcg.kg.min-1.

Propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously for induction of general anaesthesia. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to maintain a BIS value of between 40-60. Intravenous remifentanil infusion between 0.1-0.2 mcg/kg/min will be given and this will be titrated to provide optimal haemodynamic parameters.

Michael G. IRWIN, M.B. Ch.B

Amulet CM Ip, BSN

Chong

Michael G. Irwin, M.B. Ch.B

More than 80% of patients with cancer will be exposed to anaesthesia at some point in their treatment. There is increasing evidence that perioperative events, including the type of anaesthesia drugs utilised, have an impact on cancer recurrence and metastases.

Although potentially and theoretically curative, surgical resection, manipulation and trauma may disseminate tumour cells and reduce immunity. There have been a number of suggestions as to why cancer may be, paradoxically, worsened by surgery and what methods may be used to mitigate this. One of these is propofol based total intravenous anaesthesia (TIVA), whereby the traditional inhalational anaesthetic drugs are avoided. Commonly used inhalational drugs, such as sevoflurane and desflurane, are pro-inflammatory.

Propofol, however, has anti-inflammatory and anti-oxidative properties, induces apoptosis and has specific inhibitory effects on tumour cell growth in vitro. Laboratory investigations, animal models, retrospective clinical studies and initial clinical research are producing evidence that inhalational anaesthesia facilitates tumour recurrence and metastasis, whilst TIVA can prolong survival.

This randomised, controlled trial will look at the effects on DNA damage and biomarkers of immunity and inflammation of inhalational anaesthesia versus TIVA in patients undergoing surgery for hepatocellular carcinoma, a common tumour in the Southern Chinese population, for whom surgery is potentially-curative. It will focus on subjects undergoing open and laparoscopic hepatectomy and investigate changes in biomarkers of inflammation, immunity and gene expression from the patients' blood samples taken before, during and after surgery.

Patients will also be followed-up for cancer recurrence, morbidity and five-year mortality. Results could represent a breakthrough in knowledge of how anaesthetic agents impact the results of cancer surgery, and have important implications for a more disease- sensitive approach to improving management and outcomes in these patients.

Pre-operative care

Pre-operative assessment will be performed at the preadmission clinic or at the general ward. Patients will be fasted for intake of solid food for 6 hours and clear liquids for 2 hours. Sedative premedication will not be prescribed.

Anaesthesia and intraoperative care

SEVO Group

Patients from the SEVO group will be anaesthetized according to the following protocol:

On arrival at the operation theatre, an intravenous cannula will be inserted. Standard monitoring with pulse oximeter, non-invasive blood pressure, and three-lead electrocardiogram will be applied prior to induction. Non-invasive blood pressure (NIBP) will be checked at least every 5 minutes throughout the operation. An arterial line may be inserted at the discretion of the anaesthetist before or after induction, with invasive blood pressure monitoring in lieu of NIBP if deemed necessary. Additional intravenous cannulas or central lines may also be inserted to facilitate fluid therapy, measure the central venous pressure or administer drugs, also at the discretion of the attending anaesthetist.

Anaesthesia will be induced with titrated, manual propofol injection of 1-2 mg.kg-1. Remifentanil infusion will be given for analgesia at a rate of 0.1 - 0.35 mcg.kg.min-1 as required, according to haemodynamic parameters. Cisatracurium 0.15 mg.kg-1 or atracurium 0.5 mg.kg-1 will be used for muscle relaxation. Tracheal Intubation will be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane at 0.5- 1 MAC, air and oxygen will be used for maintenance of general anaesthesia. Processed EEG (BIS™) will be utilized to monitor depth of anaesthesia, aiming at a BIS value of 40-60. FiO2 will be kept between 35-50% to maintain and SaO2 of \> 95%. Further muscle relaxants can be given during the operation if required.

In accordance with British consensus guidelines on intravenous fluid therapy for Adult Surgical Patients \[22\], intraoperative fluid or blood loss will be initially replaced with balanced crystalloid solution, preferably Plasmalyte A (a physiologically balanced electrolyte solution similar to extracellular fluid), for up to 20% of body volume, with additional fluid replacement with colloid or crystalloid at the discretion of the anaesthetist. Intravenous phenylephrine, ephedrine or fluid administration may also be given for management of hypotension. Intravenous anti-hypertensive agents such as beta blockers (e.g. esmolol, labetalol) and glyceryl trinitrate can be given if hypertension occurs.

Patients will receive standardized opioid analgesia of 0.1 mg.kg-1 intravenous morphine intra-operatively followed by patient-controlled analgesia (PCA) morphine post-operatively, as well as local anaesthesia (0.5% levobupivacaine) injected in the areas of surgical incision during wound closure for pain control.

Forced air warming blankets will be used with the aim of keeping a core temperature of 35.5-37.5 degrees Celsius. Ondansetron 4mg IV will be given 30 minutes before end of surgery.

Sevoflurane and remifentanil infusion will be switched off at the end of the procedure. Reversal of muscle relaxation can be achieved if required with neostigmine 50 mcg.kg-1 IV and atropine 20 mcg.kg-1 IV. Patients will subsequently be transferred to the post anaesthetic care unit (PACU) for monitoring for at least 30 minutes.

TIVA Group

Patients in the TIVA group will be anaesthetized according to the following protocol:

Monitoring and other anaesthetic procedures including the management of hypertension and hypotension will be the same as SEVO group. Induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Sevoflurane will not be used, and oxygen and air would be given to provide a FiO2 of 30-50%.

Target controlled infusion (TCI) with a modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia and titrated to effect. The usual effect site concentration is 1.5-3 mcg.ml-1 and BIS monitoring will also be used to produce a value of between 40-60. As with patients in the SEVO group, remifentanil will be infused at a rate of between 0.1-0.3 mcg.kg.min-1.

Post-operative care for both groups In the recovery room after surgery, numerical rating pain score (NRS) will be used to assess level of pain. Patients will select a whole number (0-10 integers) that best reflects the intensity of his/her pain, in which 10 represents the maximal imaginable pain. Boluses of 2 mg intravenous morphine will be given every 5 minutes until the numerical rating scale (NRS) is less than or equal to 4/10. A patient controlled analgesia (PCA) machine will then be connected. The machine will be configured to give 1 mg of morphine whenever the patient demands with the lockout duration set to 5 minutes. No background infusion will be given and the maximum dose limit will be 0.1 mg.kg-1 per hour of morphine.

On post-operative day 1, when the patient resumes a fluid diet, oral celecoxib 200 mg will be given twice daily for 3 days.

Whilst on PCA morphine, the patient's respiratory rate, oxygen saturation (SpO2) and sedation score will be monitored every hour. Heart rate and blood pressure will be checked every 4 hours. NRS pain scores at rest and during cough/movement, cumulative PCA morphine doses, and number of PCA demands/goods delivered, and side effects (nausea, vomiting, dizziness, hypotension, desaturation) will be recorded every 4 hours. Patients will be assessed by a "pain team" every day to determine sufficiency of analgesia, as per usual practice.

Patients will be kept on PCA morphine for at least 2 days. If NRS pain scores during cough/ movement on postoperative day 2 are less than or equal to 3/10, PCA morphine will be stopped. PCA morphine will be continued if NRS is equal or greater than 4, or if the patient remains on a high PCA use. Assessment for analgesia will be conducted daily. Evaluation for complications will be required if NRS pain score is 4 or higher on postoperative day 5. The patient will be further managed at the discretion of the anaesthetist.

After PCA morphine has been withdrawn, NRS pain scores at rest and during cough/ movement, as well as the dose and frequency of rescue analgesia used will be charted once a day until discharge.

Effects of TIVA Versus Inhalational Anaesthesia on Circulating Tumour Cells in Hepatocellular Carcinoma Patients

Effects of Mode of Anaesthesia on Circulating Tumour Cells in Patients Undergoing Inhalational Versus Total Intravenous Anaesthesia for Hepatocellular Carcinoma Surgery : A Randomised Controlled Trial

the detection of a two-fold difference between the pre-operative blood sample and 24-hour post-operative blood sample in HIF-1 gene expression in the SEVO group, and a less than two-fold difference in the same samples of the TIVA group

Change in the incidence of two-year recurrence between TIVA and SEVO group

The level of Gene expression (HIF-1, IL-6, TNF-alpha) will be measured from the RNA/cDNA extracted from blood sample taken at different timepoints by Polymerase chain reaction test

The level of DNA damage will be measured from the white blood cells extracted from blood sample taken at different timepoints by Comet Assay test

The level of C-reactive protein will be measured from the Plasma extracted from blood sample taken at different timepoints by Commercial Kit

The level of Glutathione Peroxidase will be measured from the Red blood cells extracted from blood sample taken at different timepoints by Commercial Kit

The level of Superoxide dismutase will be measured from the Red blood cells extracted from blood sample taken at different timepoints by Commercial Kit

The level of Oxidative damage DNA (8-oxoGuo, 8-oxodG) will be measured from the Plasma extracted by Commercial Kit

The level of tumor necrosis factor (IL-6, TNF-alpha, HIF-1) will be measured from the Plasma extracted by An enzyme-linked immunosorbent assay (ELISA)

The number of Circulating tumour cells will be isolated from the blood samples taken at different timepoints by filtration and count under microscope

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
An Algorithm for Intra-operative Goal-directed Haemodynamic Management in Non-cardiac Surgery	NCT01384097	Fracture of Sur... Colonic Tumor Stage IIIB Ovar... Neoplasm of Hea...		18 Years -	Charite University, Berlin, Germany
Efficacy and Optimal Dose Selection of Intranasal Dexmedetomidine During Breast Lumpectomy Under Local Anaesthesia	NCT02675049	Intranasal Dexm...	0.9% saline dexmedetomidine... dexmedetomidine... Dexmedetomidine...	20 Years - 60 Years	Tianjin Medical University Cancer Institute and Hospital
An Algorithm for Intra-operative Goal-directed Haemodynamic Management in Non-cardiac Surgery	NCT01384097	Fracture of Sur... Colonic Tumor Stage IIIB Ovar... Neoplasm of Hea...		18 Years -	Charite University, Berlin, Germany
Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study.	NCT05439005	Breast Cancer	Dexmedetomidine	18 Years -	Institut Curie
Efficacy and Optimal Dose Selection of Intranasal Dexmedetomidine During Breast Lumpectomy Under Local Anaesthesia	NCT02675049	Intranasal Dexm...	0.9% saline dexmedetomidine... dexmedetomidine... Dexmedetomidine...	20 Years - 60 Years	Tianjin Medical University Cancer Institute and Hospital
Effectiveness of Ultrasound Guided PECS Block on Opioid Consumption and Patient Satisfaction Through Adequate Pain Control Following Breast Cancer Surgery.	NCT04343807	Breast Neoplasm... Pain, Postopera... Pain Analgesia Anaesthesia Breast Cancer	PECS Block Control Group	18 Years - 65 Years	Aga Khan University
Cardiopulmonary Exercise Testing and Preoperative Risk Stratification	NCT00737828	Colorectal Canc... Anaesthesia Critical Illnes...	Perioperative c...	18 Years -	University College London Hospitals
Effects of TIVA Versus Inhalational Anaesthesia on Circulating Tumour Cells in Hepatocellular Carcinoma Patients	NCT04601961	Circulating Tum... Hepatocellular ...	Propofol Sevoflurane	18 Years - 80 Years	The University of Hong Kong
Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study.	NCT05439005	Breast Cancer	Dexmedetomidine	18 Years -	Institut Curie

Spots Global Cancer Trial Database for anaesthesia

Every month we try and update this database with for anaesthesia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for anaesthesia

Every month we try and update this database with for anaesthesia cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for anaesthesia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.